22 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
19 May 23
Regulation FD Disclosure
9:15am
years (27 - 74) Sex, n (%) Female 21 (51%) 3 (33%) 24 (48%) Male 20 (49%) 6 (67%) 26 (52%) Race, n (%) White 38 (93%) 8 (89%) 46 (92%) Black or African … Baseline Clinical effect on injected tumor and uninjected tumor Day 168 Day 280 Day 0 Black hole within tumor image is injection site106 PFU dose 56 YOM
8-K
EX-99.1
CADL
Candel Therapeutics Inc
6 Dec 22
Regulation FD Disclosure
8:01am
(%) Race n (%) Stage III 8 (15) Black/African American 7 (13) Stage IV 44 (85) Asian 1 (2) Histology n (%) White 41 (79) Non-Squamous 37 (71) Unknown 3 … Race White/Caucasian 34(83) Methylated 16(39) Unmethylated 25(61) Black/African American 3(7) American Indian or IDH* * 1(2) Alaska Native Wild type 39
8-K
EX-99.1
CADL
Candel Therapeutics Inc
6 Jun 22
Regulation FD Disclosure
8:37am
activity of CAN-3110 in recurrent HGG patient with abscopal effect Secondary lesion Injected lesion Baseline Day 168 Day 0 Day 56 Day 111 Day 280 Black
DEF 14A
CADL
Candel Therapeutics Inc
2 Sep 22
Definitive proxy
8:30am
Not
Disclose
Gender
Part I: Gender Identity
Directors
Part II: Demographic Background
African American or Black
Alaskan Native or Native American
Asian … , MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:
KEEP THIS PORTION FOR YOUR RECORDS
10-K
ht5vu4d8a
29 Mar 22
Annual report
8:46am
10-Q
i9kmxmqul39u6dxes
8 Sep 21
Quarterly report
8:37am
S-1/A
30w 2gw657ylo
16 Jul 21
IPO registration (amended)
6:07am
S-1
v2iotx7bn1p5
25 Jun 21
IPO registration
5:28pm